Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department
NCT07667621Phase 1Recruiting
- Sponsor
- University of South Florida
- Start
- Sep 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of rimegepant and zavegepant in migraine (2 arms), sponsored by University of South Florida. Primary endpoint: Pain relief at 2 hours without rescue medication. Started Sep 2026; status: recruiting.
02
Drugs
rimegepantzavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07667621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07667621.